Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
- Sponsor
- Rep. Arrington, Jodey C. [R-TX-19]
- Committees
- Ways and Means Committee (primary)
- Last action
- Oct 3, 2025
Bottom line
The bill expands Medicare to cover new multi-cancer early detection screening tests, aiming to improve early cancer diagnosis for seniors, while establishing initial payment and usage guidelines.
What it actually does
This bill amends Title XVIII of the Social Security Act to establish Medicare coverage for multi-cancer early detection screening tests, effective January 1, 2028. It defines these tests, sets initial payment amounts, and outlines specific age and frequency limitations for coverage. The bill also clarifies that this new coverage does not replace existing Medicare coverage for other cancer screening tests.
Proponents argue
Proponents argue that providing Medicare coverage for multi-cancer early detection tests is a critical step in leveraging scientific advancements to save lives. They contend that early detection of multiple cancer types can lead to more effective treatments, better patient outcomes, and potentially reduce the long-term costs associated with treating advanced cancers.
Opponents contend
Opponents or cautious observers might express concerns about the potential for widespread adoption of these tests before sufficient real-world evidence of their clinical utility and cost-effectiveness is established. They may also raise issues regarding the potential for false positives leading to unnecessary diagnostic procedures, patient anxiety, and the overall fiscal impact on the Medicare program.
The bill is concise and can be read quickly, allowing ample time for a thorough evaluation of its provisions.
Section 2(a), amending Section 1861 of the Social Security Act
Establishes Medicare Coverage for Multi-Cancer Early Detection Screening Tests
This provision adds multi-cancer early detection screening tests to the list of services covered by Medicare. These tests must be cleared or approved by the FDA, be based on genomic sequencing of blood or comparable biological samples, and be determined by the Secretary of Health and Human Services to be reasonable, necessary, and appropriate for Medicare beneficiaries. Coverage for these tests will begin on January 1, 2028.
Supporters argue
Supporters argue that this provision is essential for modernizing Medicare benefits to include cutting-edge technology that can detect multiple cancers at earlier, more treatable stages, ultimately saving lives and improving health outcomes for seniors.
Critics contend
Critics may contend that covering these tests before extensive long-term data on their clinical efficacy and cost-effectiveness is fully established could lead to significant Medicare expenditures without guaranteed improvements in patient mortality or quality of life, potentially also increasing false positives and unnecessary follow-up procedures.
Tradeoffs
The provision balances the desire to provide access to innovative medical technology with the need for regulatory approval and a determination of medical necessity and appropriateness for a broad Medicare population, while managing potential costs.
Section 2(b)(1), amending Section 1834 of the Social Security Act
Establishes Payment Amounts and Limitations for Multi-Cancer Early Detection Screening Tests
This section sets the payment amount for multi-cancer early detection screening tests. Before January 1, 2031, the payment will be equal to that of a multi-target stool screening DNA test. On or after January 1, 2031, the payment will be the lesser of that amount or the amount determined under a separate section (1834A). It also imposes limitations: no payment will be made for individuals who have reached a certain age (starting at 68 in 2028, increasing by one year annually) or if a test was performed in the preceding 11 months. These limitations cease if the U.S. Preventive Services Task Force (USPSTF) recommends the test with an A or B grade.
Section 2(c)
Clarifies Impact on Existing Cancer Screening Coverage
This section explicitly states that the new Medicare coverage for multi-cancer early detection screening tests does not affect existing Medicare coverage for other specific cancer screening tests, such as those for breast, cervical, colorectal, lung, or prostate cancer. It also clarifies that undergoing one type of cancer screening does not prevent coverage for the other, nor does it preclude the use of multi-cancer tests as diagnostic or confirmatory tools.
Requires the Secretary to use the National Coverage Determination (NCD) process for making coverage determinations for new multi-cancer early detection screening tests.
Section 1861(nnn)(2) of the Social Security Act, as added by Section 2(a)(2) of the bill
Why it matters:This is standard legislative practice for specifying administrative procedures related to new benefits.
Case for: Using the NCD process ensures a transparent, evidence-based approach to evaluating new tests, allowing for public input and expert review before coverage is finalized, which can enhance confidence in the tests' efficacy and appropriateness.
Case against: The NCD process can be lengthy, potentially delaying access to promising new tests for beneficiaries. Critics might argue for a more expedited review process given the urgency of cancer detection.
Estimated impact: Ensures a structured, public review process for future test approvals, potentially impacting the timeline for new tests to gain Medicare coverage.
Specifies that the age limitation for multi-cancer early detection screening tests will start at 68 years in 2028 and increase by 1 year annually for succeeding years.
Section 1834(aa)(2)(B) of the Social Security Act, as added by Section 2(b)(1) of the bill
Why it matters:This is a technical detail for phasing in an eligibility requirement, common in legislative drafting.
Case for: This gradual increase in the age threshold allows for a phased implementation, potentially managing initial costs and allowing the healthcare system to adapt to the new screening paradigm, while still expanding access over time.
Case against: Critics might argue that a gradually increasing age threshold could create confusion or inequity, as beneficiaries of different ages would become eligible at different times, potentially delaying access for those who could benefit from earlier screening.
Estimated impact: Controls the initial pool of eligible beneficiaries, gradually expanding access over time.
Stipulates that for tests furnished on or after January 1, 2031, the payment amount will be the lesser of the initial payment amount (linked to multi-target stool DNA tests) or the amount determined under section 1834A.
Section 1834(aa)(1)(B) of the Social Security Act, as added by Section 2(b)(1) of the bill
Why it matters:This is a technical detail for future payment adjustments, common in complex healthcare legislation.
Case for: This provision allows for a future recalibration of payment rates based on more specific data or updated methodologies (Section 1834A), ensuring that Medicare payments remain appropriate and cost-effective as the technology matures and more information becomes available.
Case against: Manufacturers might argue that this future payment uncertainty could disincentivize investment in the development and improvement of these tests, particularly if the Section 1834A determination leads to significantly lower reimbursement rates.
Estimated impact: Introduces a future mechanism for adjusting payment rates, potentially impacting manufacturer profitability and Medicare expenditures.